Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by RMR Wealth Builders

RMR Wealth Builders lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,239 shares of the pharmaceutical company’s stock after purchasing an additional 351 shares during the quarter. RMR Wealth Builders’ holdings in Vertex Pharmaceuticals were worth $1,707,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in VRTX. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $25,000. Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $27,000. GHP Investment Advisors Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded down $2.55 on Friday, hitting $409.56. The company had a trading volume of 1,687,826 shares, compared to its average volume of 1,512,628. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The company has a market cap of $105.47 billion, a PE ratio of -205.81 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The business has a 50 day moving average of $450.11 and a 200 day moving average of $468.49.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 earnings per share. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent analyst reports. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. UBS Group raised their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Wells Fargo & Company cut their target price on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Bank of America dropped their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research note on Thursday, December 19th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.